FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892011855> ?p ?o ?g. }

• W2892011855 endingPage "62" @default.
• W2892011855 startingPage "54" @default.
• W2892011855 abstract "Uveitis is inflammation of the uvea which consists of the iris, ciliary body and the choroid of the eye. Uveitis can lead to impaired vision and is responsible for 10% of all cases of blindness globally. Using an endotoxin-induced uveitis (EIU) rodent model, our previous data implicated the endogenous cannabinoid system (ECS) in the amelioration of many of the components of the inflammatory response. Here, we test the hypothesis that the reduction in inflammatory mediators in the EIU model by the CB2 agonist, HU308, is associated with changes in ECS endogenous ligands as well as related lipids, prostaglandins (PGs), 2-acyl glycerols, and lipoamines. Analysis of leukocytes and neutrophils, CB2 mRNA, and 26 lipids in the eye of WT mice after EIU induction and HU308 treatment were compared to the same analyses in the CB2 knock-out (CB2 KO) mouse. Endothelial leukocyte adhesion and neutrophil migration were significantly increased in both WT and CB2 KO after EIU. HU308 significantly reduced the leukocyte adhesion and neutrophil recruitment in the WT animals. HU308 also significantly reduced leukocyte adhesion in the CB2 KO mouse, yet, had no effect on neutrophil infiltration suggesting an important off-target effect of HU308. Lipidomics profiles revealed significant increases in 6 non-ECS lipids after EIU in the WT and that HU308 effectively reduced these back to control levels; in addition, HU308 increased levels of 2-acyl glycerols and decreased all N-acyl glycines. CB2 KOs with saline-injection compared to WT had significantly elevated levels of 2-acyl glycerols, whereas levels of N-oleoyl ethanolamine (OEA), N-stearoyl ethanolamine (SEA), and PGE2 were reduced. CB2 KOs with EIU had 13 lipids that were significantly lower than WT with EIU including 4 N-acyl glycines. HU308 had no effect on lipid concentrations in the CB2 KOs with EIU, however, it did cause further reductions on 3 additional lipids compared to saline controls. HU308 appears to be acting at a non-CB2 target for the reduction of leukocyte infiltration in the EIU model; however, our data suggest that HU308 is working through CB2 to reduce neutrophil migration and for the regulation of multiple lipid signaling pathways including PGs, lipoamines, and 2-acyl glycerols. These data implicate ocular CB2 as a key component of lipid signaling in the eye and part of the regulatory processes of inflammation." @default.
• W2892011855 created "2018-09-27" @default.
• W2892011855 creator A5009261994 @default.
• W2892011855 creator A5018247087 @default.
• W2892011855 creator A5030838197 @default.
• W2892011855 creator A5037819900 @default.
• W2892011855 creator A5063933580 @default.
• W2892011855 creator A5074795979 @default.
• W2892011855 creator A5081516303 @default.
• W2892011855 creator A5086234142 @default.
• W2892011855 date "2018-11-01" @default.
• W2892011855 modified "2023-10-18" @default.
• W2892011855 title "Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye" @default.
• W2892011855 cites W1503696655 @default.
• W2892011855 cites W1504900766 @default.
• W2892011855 cites W1543781012 @default.
• W2892011855 cites W1557215935 @default.
• W2892011855 cites W1819429514 @default.
• W2892011855 cites W1964395752 @default.
• W2892011855 cites W1969338731 @default.
• W2892011855 cites W1976922940 @default.
• W2892011855 cites W1978227204 @default.
• W2892011855 cites W1979841486 @default.
• W2892011855 cites W1989073099 @default.
• W2892011855 cites W1989263093 @default.
• W2892011855 cites W1991527836 @default.
• W2892011855 cites W1994513849 @default.
• W2892011855 cites W2002785222 @default.
• W2892011855 cites W2010913188 @default.
• W2892011855 cites W2014838450 @default.
• W2892011855 cites W2015264989 @default.
• W2892011855 cites W2015943785 @default.
• W2892011855 cites W2018828507 @default.
• W2892011855 cites W2021866751 @default.
• W2892011855 cites W2025896767 @default.
• W2892011855 cites W2029974988 @default.
• W2892011855 cites W2042676931 @default.
• W2892011855 cites W2044609482 @default.
• W2892011855 cites W2056188558 @default.
• W2892011855 cites W2057976080 @default.
• W2892011855 cites W2079105267 @default.
• W2892011855 cites W2085741941 @default.
• W2892011855 cites W2087157662 @default.
• W2892011855 cites W2096973688 @default.
• W2892011855 cites W2099041853 @default.
• W2892011855 cites W2111152176 @default.
• W2892011855 cites W2112755850 @default.
• W2892011855 cites W2118998202 @default.
• W2892011855 cites W2119417389 @default.
• W2892011855 cites W2122992077 @default.
• W2892011855 cites W2124994524 @default.
• W2892011855 cites W2127043851 @default.
• W2892011855 cites W2132442850 @default.
• W2892011855 cites W2141753787 @default.
• W2892011855 cites W2142488420 @default.
• W2892011855 cites W2144328304 @default.
• W2892011855 cites W2150117087 @default.
• W2892011855 cites W2151498881 @default.
• W2892011855 cites W2154278853 @default.
• W2892011855 cites W2156019215 @default.
• W2892011855 cites W2157406543 @default.
• W2892011855 cites W2160781696 @default.
• W2892011855 cites W2169838204 @default.
• W2892011855 cites W2232206974 @default.
• W2892011855 cites W2295029605 @default.
• W2892011855 cites W2342960672 @default.
• W2892011855 cites W2461255045 @default.
• W2892011855 cites W2558614687 @default.
• W2892011855 cites W2623918826 @default.
• W2892011855 cites W2735727788 @default.
• W2892011855 doi "https://doi.org/10.1016/j.prostaglandins.2018.09.004" @default.
• W2892011855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30232034" @default.
• W2892011855 hasPublicationYear "2018" @default.
• W2892011855 type Work @default.
• W2892011855 sameAs 2892011855 @default.
• W2892011855 citedByCount "15" @default.
• W2892011855 countsByYear W28920118552018 @default.
• W2892011855 countsByYear W28920118552019 @default.
• W2892011855 countsByYear W28920118552020 @default.
• W2892011855 countsByYear W28920118552021 @default.
• W2892011855 countsByYear W28920118552022 @default.
• W2892011855 countsByYear W28920118552023 @default.
• W2892011855 crossrefType "journal-article" @default.
• W2892011855 hasAuthorship W2892011855A5009261994 @default.
• W2892011855 hasAuthorship W2892011855A5018247087 @default.
• W2892011855 hasAuthorship W2892011855A5030838197 @default.
• W2892011855 hasAuthorship W2892011855A5037819900 @default.
• W2892011855 hasAuthorship W2892011855A5063933580 @default.
• W2892011855 hasAuthorship W2892011855A5074795979 @default.
• W2892011855 hasAuthorship W2892011855A5081516303 @default.
• W2892011855 hasAuthorship W2892011855A5086234142 @default.
• W2892011855 hasConcept C118487528 @default.
• W2892011855 hasConcept C126322002 @default.
• W2892011855 hasConcept C134018914 @default.
• W2892011855 hasConcept C16613235 @default.
• W2892011855 hasConcept C169760540 @default.
• W2892011855 hasConcept C170493617 @default.
• W2892011855 hasConcept C180899940 @default.

• next